Eledon Pharmaceuticals

Eledon Pharmaceuticals is a biotechnology company listed on NASDAQ as ELDN, whose lead asset tegoprubart is an anti-CD40L antibody built to prevent transplant rejection without calcineurin inhibitors. In type 1 diabetes it is the immunosuppressant used in an investigator-initiated islet transplant trial at the University of Chicago run by Dr. Piotr Witkowski, where Eledon reported that all 12 patients in the trial became insulin independent, a cohort followed for about eight months on average. Eledon's own lead program is elsewhere: the Phase 2 BESTOW trial in kidney transplantation, which reported a mean 12-month estimated glomerular filtration rate of about 69. The company is not T1D-exclusive, and its stated programs span kidney and liver transplantation, xenotransplantation, islet transplantation, and amyotrophic lateral sclerosis.

Location

Irvine, California, U.S.

Founded

2020